Takeda announced this week that it received FDA approval for its Eohilia (budesonide oral suspension) therapy. This makes Eohilia the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE). Takeda plans to offer it in 2 mg/10 mL convenient, single-dose stick packs by the end of February. Eohilia, a…
Report: Pharma kicks off year with drug price hikes
Reuters reports that a number of big-name drugmakers, including Pfizer, Sanofi and Takeda plan to raise drug prices to start the year. According to the report, the price hikes apply to more than 500 drugs. Excluding different doses and formulations, the reach extends to more than 140 brands of drugs. Reuters said healthcare research firm 3…
Takeda and Capsida announce manufacturing plant investments in California
Takeda Pharmaceuticals (NYSE:TAK) has announced that it is investing $126 million to expand a production facility in Thousand Oaks, one of the largest cities in Ventura County, California. The money will support constructing a new 15,000-ft2 manufacturing facility and renovating an existing 14,000–ft2 plant. The mayor of the city, Claudia Bill-de la Peña, joined Takeda officials…